Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lillian Ruiheng Chen

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
JAMA Oncology|June 4, 2026
Fluids for Immune Checkpoint Inhibitor Diabetic KetoacidosisLillian Ruiheng Chen, Tim Cooksley, Safwaan Adam
Diabetes Care|July 1, 2026
Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD AntibodiesLillian Ruiheng Chen, Tim Cooksley, Rupinder Kochhar, et al.
Rheumatology (Oxford, England)|June 25, 2025
Higher comorbidities associated with less improvement in disease activity in early rheumatoid arthritis: results from CATCH cohortSafoora Fatima, Janet E Pope, Lillian-Ruiheng Chen, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
JAMA Oncology|June 4, 2026
Fluids for Immune Checkpoint Inhibitor Diabetic KetoacidosisLillian Ruiheng Chen, Tim Cooksley, Safwaan Adam
Diabetes Care|July 1, 2026
Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD AntibodiesLillian Ruiheng Chen, Tim Cooksley, Rupinder Kochhar, et al.
Rheumatology (Oxford, England)|June 25, 2025
Higher comorbidities associated with less improvement in disease activity in early rheumatoid arthritis: results from CATCH cohortSafoora Fatima, Janet E Pope, Lillian-Ruiheng Chen, et al.
Pageof 1